Arcadia Biosciences implements 1-for-40 reverse stock split effective March 1, 2023

Arcadia Biosciences, Inc.

Reverse stock split of common stock at 1:40 ratio, effective 12:01 a.m. ET on March 1, 2023.
No fractional shares; odd shares rounded up to the next whole number.
Authorized shares remain 150,000,000; par value unchanged at $0.001 per share.
Stockholders approved split range (1:10 to 1:40) at Feb 15, 2023 special meeting; board selected 1:40.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Arcadia Biosciences, Inc.: Approved and filed a Certificate of Amendment to effect a 1-for-40 reverse stock split of common stock (effective 2023-03-01).

Change: charter amendment
Effective: 2023-03-01

Exact text from the filing

On February 27, 2023, Arcadia Biosciences, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-40 reverse stock split of the outstanding shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective as of 12:01 a.m. (Delaware time) on March 1, 2023 (the “Reverse Stock Split”).

View on SEC.gov

Browse all governance changes →

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-005092

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.